{
    "abstract": "Albuminuria and renal insufficiency prevalence guides popula- Chronic progressive renal impairment is usually an tion screening: Results from the NHANES III. asymptomatic condition. Community strategies to re-",
    "reduced_content": "Albuminuria and renal insufficiency prevalence guides\npopulation screening: Results from the NHANES III\n \n \n \nAlbuminuria and renal insufficiency prevalence guides popula- Chronic progressive renal impairment is usually an\ntion screening: Results from the NHANES III. asymptomatic condition. Community strategies to re-\nBackground. A number of screening criteria, applied either\nduce the incidence of end-stage renal disease (ESRD)\nat a single point in time or serially, can be used for the purpose\nmay need to integrate methods of screening and earlier\nof identifying individuals at risk of end-stage renal disease\nintervention. Randomized clinical trials best estimate the\n(ESRD). This study focused on two such criteria measured\non a single occasion, proteinuria and renal insufficiency, and clinical effectiveness of screening compared with usual\nexamined their prevalence in a sample representative of the care [1]; however, unlike other diseases [2\u00ad3], such trials\nadult U.S. non-institutionalized population. Such knowledge\ndo not exist for ESRD prevention, and may not be imme-\nguides the utility of population screening to prevent ESRD.\ndiately forthcoming. Current screening clinical practice\nMethods. The prevalence of albuminuria (microalbuminuria\nand macroalbuminuria from a random urine albumin-to-creati- guidelines and positional statements are based primarily\nnine ratio) and renal insufficiency [glomerular filtration rate on expert opinion, longitudinal studies identifying risk\n(GFR) estimated from serum creatinine] was determined in factors for ESRD, and single therapy interventional stud-\ndifferent age categories in various adult screening groups in\nies, and these guidelines do not quantify the effectiveness\nthe cross-sectional Third National Health and Nutrition Exami-\nof screening [4\u00ad9]. An estimate of the clinical effectiveness\nnation Survey (NHANES III).\nResults. A total of 14,622 adult participants were included of screening in the absence of randomized clinical trials\nin the analysis. In the general population, 8.3% and 1.0% of is possible [10], and requires knowledge of (a) the inci-\nparticipants demonstrated microalbuminuria and macroalbu-\ndence of ESRD in individuals who demonstrate certain\nminuria, respectively. To identify one case of albuminuria, one\nscreening test results; (b) the prevalence of such individu-\nwould need to screen three persons with diabetes mellitus,\nals in target groups to be screened, who at the time of\nseven non-diabetic hypertensive persons, or six persons over\nthe age of 60. When albuminuria and renal insufficiency were screening are not receiving effective interventions (such\nconsidered together, it was clear that these tests were identi- as angiotensin converting enzyme inhibitors [11\u00ad13],\nfying different segments of the population; 37% of participants\nblood pressure control [14\u00ad15], and dietary protein re-\nstriction [16]) to reduce their risk for the outcome; and\nalbuminuria. Non-albuminuric renal insufficiency was most evi-\ndent in the ages of 60 to 79; 34% of diabetics, and 63% of (c) the cumulative effectiveness of interventions to re-\nnon-diabetic hypertensives with a GFR less than 30 mL/min/ duce the incidence of ESRD, in persons who exhibit\n1.73 m2 demonstrated no albuminuria. certain screening test results. This report focuses on crite-\nConclusions. Albuminuria is prevalent, and when consid-\nria that identify individuals with a higher lifetime risk of\nered together, screening tests of albuminuria and renal insuffi-\nESRD, and the prevalence of such individuals in target\nciency measured on a single occasion identify different segments\nof the population. The prevalence of albuminuria and renal in- groups to be screened.\nsufficiency in populations of interest should be considered, as this A major challenge in identifying individuals at risk of\nknowledge has implications for the effectiveness of screening. ESRD remains that the incidence in the general popula-\ntion is low. For example, the U.S. incidence of ESRD\nKey words: mass health screening, health status indicators, kidney dis-\nease, glomerular filtration rate, proteinuria, diabetes mellitus. and laboratory criteria have been identified which pre-\ndict, from assessment on a single occasion, an increased\nincidence of ESRD. Longitudinal studies have demon-\n[19], hypertension (and higher systolic and diastolic\n 2002 by the International Society of Nephrology\nGarg et al: Albuminuria and renal insufficiency\nblood pressure) [20], hematuria [21], proteinuria (dip- Inclusion criteria for this analysis were an age of 20 years\nor more, measured serum creatinine, and determination\nstick proteinuria [21]), and an elevated serum creatinine\n[21] are all independent risk factors for ESRD in the of urinary albumin and creatinine.\ngeneral community. Other variables such as family his-\nMeasurements\ntory of kidney disease [22] and non-steroidal anti-\ninflammatory use [23, 24] also may be useful for risk Microalbuminuria/macroalbuminuria. Random day-\ntime spot urine specimens were collected from partici-\nstratification. To identify individuals with a higher inci-\ndence of ESRD by community screening, it may be nec- pants, and no albuminuria testing was performed on\nvisibly hematuric or hemoglobin dipstick-positive speci-\nessary to evaluate a number of these criteria simultane-\nously. The combination of an elevated creatinine and mens. Urinary albumin was measured by fluorescent im-\nmunoassay, and urinary creatinine by the kinetic alkaline\nproteinuria may be particularly useful in identifying a\ngroup at higher risk of progression [15, 25, 26]. Utilizing picrate (modified Jaffe\n\u00b4, Autoanalyzer) method. A uri-\nnary albumin-to-creatinine ratio (mg/mmol) was calcu-\nthese measurements in target groups delineated by older\nage, diabetes and hypertension improves the probability lated. In non-insulin dependent diabetics, a random\nurine albumin-to-creatinine ratio between 3.0 and 37.8\nof finding abnormalities with screening, and improves\nbe over 88% sensitive (SN) and specific (SP) for the\nThe purpose of the following report was to describe (1)\nthe prevalence of albuminuria (microalbuminuria and presence of microalbuminuria [albumin excretion rate\nmacroalbuminuria), (2) the relationship between albumin-\nuria and elevated serum creatinine, and (3) the number urine] [31]. Similarly a ratio greater than 37.8 mg/mmol\nneeded to screen to identify one person with albuminuria\nand/or elevated serum creatinine, in target groups deline- for the presence of macroalbuminuria [albumin excretion\nated by age, diabetes, and hypertension in a community\nsample representative of the U.S. adult non-institutional- urine]. In this article, the term `albuminuria' is used to\ndescribe the presence of either microalbuminuria or mac-\nized population.\nroalbuminuria.\nRenal insufficiency. Based on serum creatinine, parti-\nMETHODS\ncipants were grouped into three strata of renal function\nStudy design, setting and participants [glomerular filtration rate (GFR) 60, 30 to 60 and 30\nmL/min/1.73 m2], using cut-off points that have been\nThe U.S. Third National Health and Nutrition Exami-\nnation Survey (NHANES III) was used to estimate previously validated against inulin clearance [32]. In men\nserum creatinine cut points of 137 mol/L (1.5 mg/dL;\nthe prevalence of albuminuria and renal insufficiency in\nreports have examined the prevalence of elevated creati-\nnine levels [27], the prevalence of an elevated blood mL/min/1.73 m2) were used. For women serum creatinine\npressure with renal insufficiency [28], the prevalence and\nalence and association between renal insufficiency and\nolder adult malnutrition [30] in this dataset. NHANES were used.\nDiabetes mellitus/hypertension. Diabetes mellitus (DM)\nIII, sponsored by the U.S. National Center for Health\nStatistics, was a cross-sectional survey conducted from was defined as a positive response to the question, \"Have\nyou ever been told by a doctor that you have diabetes or\nfour stage, area probability sample representative of the sugar diabetes?\" Non-diabetic hypertensives were iden-\ntified as individuals with a mean systolic blood pressure\nU.S. civilian non-institutionalized population. The data\nfrom this survey are available in the public domain, and 140 mmHg, a mean diastolic blood pressure 90mmHg\ndiastolic, and/or the current use of antihypertensives [8]\nprovided the opportunity for the independent analysis\nreported here. Non-Hispanic blacks, Mexican-Ameri- in the absence of a history of diabetes. Mean blood pres-\nsures were based on a total of six measurements taken on\ncans and the elderly were oversampled in the survey to\nimprove accuracy in subgroup estimation. Data collec- two separate occasions. Non-diabetic non-hypertensives\nwere defined by an absence of diabetes and hypertension.\ntion for the survey occurred in two steps. A standardized\nhealth interview was conducted in the home, and within\nData analysis\nthe subsequent four weeks a standardized medical exam-\nination and a series of laboratory tests were conducted, The survey data were analyzed using methodology\nthat accounts for the complex sampling design, using\neither in a mobile examination center, or in the home\nof those participants who were unable to visit the center. analytic methods recommended by the U.S. National\nGarg et al: Albuminuria and renal insufficiency 2167\nTable 1. Characteristics of survey participants (%)\nCenter for Health Statistics. Sample weights were used\nto calculate prevalence estimates and to account for\nAge years\noversampling and nonresponse to the household inter-\nweighted data were missing due to incomplete diabetes\nor hypertension assessment. All analyses were conducted\nRace\nstatistical program appropriate for the analysis of com-\nplex sample survey data [35]. Weighted chi-squared tests\nor two-tailed t tests were used to examine differences Hypertensive\nbetween two proportions or means, and P values of less\nthan 0.05 were considered significant without adjustment\nSerum creatinine lmol/L\nfor multiple comparisons. Box-plots and Venn diagrams 177 in men, 146 in women\nwere graphed in Microsoft Excel. On occasion, preva-\nto-be-screened\" to identify one patient demonstrating\ntest findings of interest. This value was calculated by\nData are reported as percentage (standard error). Weighted analysis of 14,622\ndividing 1 by the prevalence of the finding of interest,\nadults. GFR, glomerular filtration rate in mL/min/1.73 m2.\nin the target group screened. For estimates of prevalence,\npoint estimates are presented with 95% confidence inter-\nvals (CI) in parentheses. The primary analysis utilized\nPrevalence of albuminuria\nvariable measurements as defined above. In supplemen-\ntary analyses two other methods of estimating creatinine The prevalence of albuminuria by age, in all partici-\nclearance [36] or GFR [37] were substituted for the pre- pants, diabetics, non-diabetic hypertensives, and non-dia-\nsented method of GFR assessment. The primary esti- betic non-hypertensives is shown in Table 2. Box-plots of\nmates presented in the results were consistent when urine albumin-to-creatinine ratio in all participants by age\nother methods of GFR were used (data not shown but are shown in Figure 1. The graphs demonstrate that statis-\navailable from authors upon request). Supplementary tically, population albuminuria is a positively skewed vari-\nanalyses used another method of defining the presence able. The cut-off points used to define microalbuminuria,\nof albuminuria, a lower gender-specific cut-off values of which have been historically derived on a statistical level\nurine albumin to creatinine ratio (men 1.9 mg/mmol, of normal (based on 95 percentiles in reference popula-\nwomen 2.8 mg/mmol) [38]. As expected, there were small tions), are somewhat arbitrary. With this limitation in\nincreases in the prevalence of albuminuria, and the over- mind, one-third (34.2%) of diabetics demonstrated al-\nlap between albuminuria and renal insufficiency, com- buminuria (microalbuminuria 28.1%, macroalbuminuria\npared with presented results. However, overall the re- 6.1%), 14.5% of non-diabetic hypertensives demonstrated\nsults were not appreciably different from the presented albuminuria (microalbuminuria 12.8%, macroalbuminuria\n1.7%), and 5.1% of non-diabetic non-hypertensives dem-\nresults (data not shown but available from authors upon\nonstrated albuminuria (microalbuminuria 4.8%, macro-\nrequest).\nalbuminuria 0.3%). The prevalence of albuminuria was\nhigher in older participants; 19.1% of participants 60 years\nRESULTS of age and older demonstrated albuminuria (16.8% mi-\nDemographic information was collected for all persons croalbuminuria, 2.3% macroalbuminuria), and 32.7% of\n20 years and over invited to participate in NHANES III octogenarians demonstrated albuminuria (28.0% micro-\nRelationship between albuminuria and\n(N  14,622) fulfilled the inclusion criteria for this study.\nrenal insufficiency\nReasons for nonresponse were multifactorial. Partici-\npants excluded from the analysis were more likely to be The prevalence of albuminuria and renal insufficiency\nolder, and to be of non-white racial background (data in all participants, diabetic participants, non-diabetic hy-\nnot shown). Characteristics for included participants are pertensive participants and non-diabetic non-hyperten-\nshown in Table 1. There were 1192 diabetic participants, sive participants, and the relationships between these\n4686 non-diabetic hypertensive participants, and 8585 two tests are shown in Table 3, and is depicted graphically\nnon-diabetic non-hypertensive participants included in as Venn diagrams in Figure 2. In each risk stratum (all\nparticipants, diabetic participants, non-diabetic hyper-\nthe sample.\nGarg et al: Albuminuria and renal insufficiency\nTable 2. Prevalence of microalbuminuria and macroalbuminuria in four study groups by age (in decades)\nWhole population\nDiabetic population\nNon-diabetic hypertensive population\nNon-diabetic non-hypertensive population\nAlbuminuria describes the presence of either microalbuminuria or macroalbuminuria. To convert albumin/creatinine from mg/mmol to mg/g, multiply by 8.84.\nThe number of participants refers to the crude, unweighted number. The cut-off point used to define microalbuminuria was greater than 3.0 mg/mmol and for\nmacroalbuminuria was greater than 37.8 mg/mmol.\nFig. 1. Box-plots of random urine albumin-to-\ncreatinine ratio for all participants. Weighted\nboxes represent the interquartile range (50%\nof the values). The line across the box indi-\ncates the median. The whiskers extend to the\ntensive participants and non-diabetic non-hypertensive 20% (95% CI, 10 to 29%) of diabetics with a GFR less\nparticipants), for all age groups, the prevalence of albu-\nminuria increased in a step-wise fashion with a decline Similarly, 43% (95% CI, 30 to 56%) of non-diabetic\nin GFR. However, as demonstrated in the Venn dia-\ngrams, it was clear that these screening tests were identi- demonstrated no albuminuria. Compared with other age\ngroups, renal insufficiency without albuminuria was least\nfying different segments of the population. For example,\nGarg et al: Albuminuria and renal insufficiency 2169\nTable 3. Prevalence of microalbuminuria and macroalbuminuria by age, and strata of renal insufficiency\nAge\nWhole population\nDiabetic population\nNon-diabetic hypertensive population\nNon-diabetic non-hypertensive population\nWeighted analysis of 14,622 survey participants. The number of participants refers to the crude, unweighted number, and groups with less than 5 persons were\nnot analyzed. Serum creatinine is in mol/L; GFR is glomerular filtration rate in mL/min/1.73 m2.\nGarg et al: Albuminuria and renal insufficiency\nFig. 2. Venn diagrams for screening of serum creatinine and random urine albumin to creatinine ratio measured on a single occasion in the adult\nwhole (A), diabetic (B), non-diabetic (C), and non-diabetic non-hypertensive (D) populations.\npronounced in younger adults and most pronounced in 20- to 39-year-old age group, one would need to screen\n84%) of non-diabetic hypertensives with a GFR less than to 27) people with hypertension who were not diabetic,\nor hypertensive, to identify one individual with micro-\nNumber needed to screen to identify one person albuminuria (regardless of GFR). Findings of renal insuf-\nwith findings ficiency and albuminuria become more prevalent with\nFor the purposes of guiding future screening initia- older age in the whole, diabetic, non-diabetic hyperten-\ntives, the prevalence of various states of albuminuria and sive and non-diabetic non-hypertensive populations, and\nrenal insufficiency in four different target groups (the the NNS is lower.\nwhole population, diabetics, non-diabetic hypertensives\nand non-diabetic non-hypertensives) for four different\nDISCUSSION\nA number of screening criteria applied either at a\nage and over) is presented in Table 4. These prevalence\nsingle time or serially, could be used to identify individu-\nestimates are presented as the number of persons one\nals at high risk of ESRD. Our study focused on two such\nwould need to screen [number-needed-to-screen (NNS)]\ncriteria measured on a single occasion (albuminuria and\nto identify one participant with the constellation of find-\nrenal insufficiency), and estimated the prevalence of these\nings specified in the left-hand column of this table. For\nconditions in the U.S. non-institutionalized population.\nexample, reading across the first row of Table 4, without\nBased on the methods described in this report, 16 adults\nscreening for serum creatinine concentration, and using\na spot collection for albumin-to-creatinine ratio in the (95% CI, 14 to 18) need to be screened to identify one\nGarg et al: Albuminuria and renal insufficiency 2171\nindividual with a serum creatinine corresponding to a lent non-diabetic hypertensives may demonstrate a se-\nrum creatinine corresponding to a GFR less than 60 mL/\ndemonstrate a level corresponding to a GFR less than\none individual with albuminuria, and this number de- 30 mL/min/1.73 m2.\nStrengths of the presented data include utilization of\ncreases in certain subgroups; 3 (95% CI, 3 to 3) diabetics,\n7 (95% CI, 6 to 8) non-diabetic hypertensives, and 6 a sample representative of the U.S non-institutionalized\npopulation, where careful standardized methods of data\nbe screened to identify one person with albuminuria. collection were employed. However, limitations of the\npresented data should be recognized. Measurements of\nOverall these data are important, because they describe\nthe frequency with which renal insufficiency and albu- serum creatinine and albuminuria are subject to consid-\nerable patient and laboratory variability, and it remains\nminuria are found in a single community screening mea-\nsurement. Albuminuria on a random spot urine albumin- unclear to what extent results from tests assessed on a\nsingle occasion identify important pathology. For exam-\nto-creatinine ratio is prevalent, particularly in diabetics,\nnon-diabetic hypertensives, and older individuals. ple, a proportion of these abnormalities may not persist\nwith subsequent testing, and for this reason the Ameri-\nIt was evident that screening tests of albuminuria and\nrenal insufficiency measured on a single occasion identi- can Diabetes Association recommends at least two of\nthree random spot urine collections done in a three to\nfied different segments of the population (Fig. 2). Ap-\nproximately 1 in every 25 persons with albuminuria dem- six month period demonstrate elevated levels before la-\nbeling a patient with microalbuminuria [4] (although\ntwo out of every three persons with a GFR less than 30 recommended strategies to overcome diagnostic uncer-\ntainty by repeated testing may reduce adherence in pri-\nmL/min/1.73 m2 demonstrated albuminuria. Non-albu-\nminuric renal insufficiency (1 out of every 3 persons with mary care settings [40], and may not improve diagnostic\naccuracy [41]). Microalbuminuria as assessed on a single\nthe ages of 60 to 79, and least evident in younger adults. occasion is common in children [29] and younger adults,\nand the prognostic importance of albuminuria in these\nWe hypothesize that certain risk factors for non-albu-\nminuric renal insufficiency (such as senescence, renal screening groups remains to be clarified. These data uti-\nlize cut-off points of urine albumin-to-creatinine ratios\nvascular disease, hypertension, and specific medication\nuse) have greatest effects in older adults. A similar find- to define overt proteinuria, and serve as a surrogate mea-\nsure for future strategies that may utilize dipstick pro-\ning was also reported in Heart Outcomes and Prevention\nEvaluation (HOPE) study, where two thirds of older teinuria testing. Individuals with hematuria and pro-\nteinuria, a small segment of the population at risk of\npatients with renal insufficiency demonstrated no albu-\nminuria [39] (individuals with a serum creatinine greater progressive renal disease [42], were excluded from this\nanalysis. The primary definitions used here to define\nthan 200 mol/L or dipstick proteinuria greater than 1\nwere not participants of this study). These results confirm albuminuria and renal insufficiency, which we have gen-\neralized to the non-institutionalized U.S. population,\nthat comprehensive screening initiatives may need to\nintegrate a number of different criteria to identify indi- were validated only in specific populations against a con-\ncurrent gold standard test (such as inulin clearance or\nviduals at risk of ESRD, and that different criteria may\nbe valuable in different age groups or at-risk populations. 24 hour albuminuria). Some of the prevalence estimates\nfor albuminuria and renal insufficiency were based on a\nThe numbers-needed-to-screen to detect albuminuria\nand renal insufficiency for four different target groups limited number of observations, and as noted in Table 4\nthese results should be interpreted with caution. Finally,\n(the whole population, diabetics, non-diabetic hyperten-\nsives, and non-diabetic non-hypertensives) and four dif- from a screening perspective, it is most clinically useful\nto characterize the prevalence of individuals with test\nyears of age and over) are presented in Table 4. We results of interest, who at the time of screening are not\nreceiving effective interventions to reduce the risk of\nhave identified the number of persons who would need\nto be screened to identify one person with a screening adverse clinical events. At the time of NHANES III, the\nmajority of interventions that reduce the risk of progres-\nstrategy specified in the left-hand column. These data\nguide future population screening initiatives, and high- sion of renal disease had not been proven. Consequently,\nidentifying the prevalence of participants in the study,\nlight the importance of knowledge of prevalence in pre-\ndicting the range of possible values for the usefulness of whose management would have been altered by renal\ninsufficiency and/or albuminuria identification, would\nscreening. For example, hypertension clinical practice\nguidelines recommend a serum creatinine measurement have been of limited utility.\nFuture evidence-based screening initiatives should ex-\nat the time of diagnosis [7, 8]. These data would predict\nthat approximately 1 in every 9 (95% CI, 8 to 10) preva- tend these findings, and aim at quantifying the number\nGarg et al: Albuminuria and renal insufficiency\nTable 4. The anticipated results of screening using different combinations of criteria with respect to a single measurement of serum creatinine\nand/or urine albumin-to-creatinine ratio\nNumber of persons needed to be screened to identify one screening finding or\ncombination of findings\nNon-diabetic Non-diabetic\nScreening strategy Whole population Diabetic population hypertensive population non-hypertensive population\n(Continued)\nGarg et al: Albuminuria and renal insufficiency 2173\nTable 4. (Continued)\nNumber of persons needed to be screened to identify one screening finding or\ncombination of findings\nNon-diabetic Non-diabetic\nScreening strategy Whole population Diabetic population hypertensive population non-hypertensive population\nPrevalence estimates are presented as the number of persons one would need to screen to identify one participant with the constellation of findings specified in\nthe left-hand column of the table.\nFor example, if screening the diabetic population ages 20 to 39 with a urine albumin-to-creatinine ratio alone, 4 persons would need to be screened to identify\none person with albuminuria. Point estimates are provided with 95% confidence intervals. Albuminuria describes the presence of either microalbuminuria or\nmacroalbuminuria. Serum creatinine is in mol/L; GFR is glomerular filtration rate in mL/min/1.73 m2.\na Estimate was based on 10 or less unweighted participants demonstrating the finding, and as a result should be interpreted with caution\nb An estimate was not possible because of the limited number of participants demonstrating finding\nof persons that need to be screened with serum creatinine a useful strategy. The importance of screening and in-\ntervening for renal disease in the larger setting of screen-\nand/or random urine albumin-to-creatinine ratio to pre-\nvent one person developing ESRD. This estimate is much ing and intervening for diabetes [47], hypertension and\nprevention of cardiovascular disease, remains to be clari-\nlarger in magnitude than the numbers-needed-to-screen\nto identify a risk factor of interest. At this time, insuffi- fied. Using screening tests of proteinuria and renal insuf-\nficiency to prevent multiple outcomes of interest (such as\ncient data on a number of intermediate steps between\nidentification of a risk factor and prevention of ESRD ESRD, renal insufficiency complications, cardiovascular\nevents or mortality) will improve the efficacy of screen-\nare available to permit reliable numeric estimations of\nthe numbers-needed-to-screen to prevent adverse clini- ing, recognizing that the presence of albuminuria may\nhave important predictive validity for future cardiovas-\ncal events. A better understanding of community ESRD\nincidence, risk factor prevalence, existing intervention cular clinical events at cut-off levels below those stan-\ndardized with concurrent gold standard tests [48]. Meth-\nuse, and cumulative intervention effectiveness will guide\nthis estimate. Furthermore, from a health services per- ods of valuing clinical events (such as distinguishing\nESRD in younger vs. older persons) may require other\nspective, many other issues need to be addressed to\nachieve effective screening strategies. The economics of statistical measures (such as quality of life years lost) to\nbe considered in the assessment of the potential value\nscreening, intervention application, and acquired ESRD\nneed to be understood to develop comprehensive, cost- of screening to society.\nIn summary, these data demonstrate that a finding of\neffective strategies [43, 44]. The ethics of screening, in-\ncluding the harm associated with labeling [45], and down- albuminuria on a single random spot urine albumin-to-\ncreatinine ratio is prevalent, particularly in diabetics,\nstream effects of false-positive results (such as patient\nanxiety and increased health care utilization) require non-diabetic hypertensives, and older individuals. When\nconsidered together, single observations of albuminuria\nconsideration. Methods of screening delivery, such as\npatient-, primary care physician-, or laboratory-initiated and renal insufficiency identify different segments of the\npopulation. To be comprehensive, screening initiatives\nscreening should be examined. The identification of indi-\nviduals at risk, by using pre-existing data in laboratory may need to integrate a number of different criteria to\nidentify individuals at risk of ESRD. The prevalence\nsurveillance programs [46], is opportunistic and may be\nGarg et al: Albuminuria and renal insufficiency\n14. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of\nof renal insufficiency and proteinuria in populations of\nantihypertensive agents on proteinuria and renal function. Arch\n15. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control,\nimplications on the effectiveness of screening.\nproteinuria, and the progression of renal disease. The Modification\n"
}